Journal of International Oncology ›› 2024, Vol. 51 ›› Issue (4): 245-248.doi: 10.3760/cma.j.cn371439-20231203-00041
Previous Articles Next Articles
Received:2023-12-03
Revised:2024-03-06
Online:2024-04-08
Published:2024-05-10
"
| 病例 | 性别 | 年龄 （岁） | 病理类型 | Ann Arbor 分期 | B症状 | 结外 侵犯 | IPI评分 （分） | ECOG评分 （分） | 前期治疗 线数 | 前期使用 PD-1 抑制剂 | 曾行 auto-HSCT | 从确诊到 使用BV 时间（月） | 疗效 评估 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 女 | 49 | 结节硬化型 | Ⅱ期 | 无 | 无 | 1 | 0 | 3 | 是 | 否 | 36 | CR |
| 2 | 男 | 68 | 混合细胞型 | ⅢE期 | 有 | 有 | 3 | 1 | 6 | 是 | 否 | 100 | PD |
| 3 | 男 | 52 | 结节硬化型 | ⅢE期 | 有 | 有 | 4 | 2 | 5 | 是 | 否 | 89 | CR |
| 4 | 女 | 47 | 结节硬化型 | Ⅳ期 | 有 | 有 | 3 | 0 | 5 | 是 | 否 | 118 | CR |
| 5 | 男 | 15 | 结节硬化型 | Ⅳ期 | 有 | 有 | 3 | 0 | 6 | 是 | 是 | 57 | CR |
| 6 | 女 | 31 | 结节硬化型 | Ⅳ期 | 有 | 有 | 3 | 2 | 6 | 是 | 是（2次） | 92 | PR |
| 7 | 男 | 75 | 混合细胞型 | Ⅳ期 | 有 | 有 | 5 | 2 | 2 | 是 | 否 | 18 | CR |
| 8 | 女 | 29 | 结节硬化型 | ⅢE期 | 无 | 有 | 2 | 1 | 4 | 是 | 是 | 82 | PR |
| 9 | 男 | 52 | 结节硬化型 | Ⅲ期 | 有 | 无 | 2 | 1 | 3 | 是 | 是 | 38 | PR |
| 10 | 男 | 42 | 结节硬化型 | Ⅱ期 | 无 | 无 | 1 | 0 | 2 | 是 | 否 | 30 | SD |
| 11 | 女 | 18 | 结节硬化型 | Ⅲ期 | 无 | 无 | 2 | 0 | 4 | 是 | 否 | 19 | PR |
| 12 | 男 | 25 | 富于淋巴细胞型 | Ⅲ期 | 无 | 有 | 1 | 1 | 2 | 是 | 否 | 76 | PR |
"
| 不良反应 | 1级 | 2级 | 3级 | 4级 | 合计 |
|---|---|---|---|---|---|
| 贫血 | 4 | 1 | 0 | 0 | 5 |
| 中性粒细胞减少 | 1 | 0 | 0 | 1 | 2 |
| 血小板减少 | 1 | 0 | 0 | 0 | 1 |
| 周围神经病 | 0 | 4 | 0 | 0 | 4 |
| 疲乏 | 4 | 0 | 0 | 0 | 4 |
| 转氨酶升高 | 1 | 2 | 0 | 0 | 3 |
| 输液反应 | 0 | 2 | 0 | 0 | 2 |
| 免疫相关性皮疹 | 0 | 2 | 0 | 0 | 2 |
| 脱发 | 2 | 0 | 0 | 0 | 2 |
| 肌酐升高 | 0 | 1 | 0 | 0 | 1 |
| 上呼吸道感染 | 0 | 1 | 0 | 0 | 1 |
| 食欲减退 | 1 | 0 | 0 | 0 | 1 |
| [1] | Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress[J]. CA Cancer J Clin, 2018, 68(2): 116-132. DOI: 10.3322/caac.21438. |
| [2] | 中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. DOI: 10.3760/cma.j.cn112152-20210516-00382. |
| [3] |
Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis[J]. Am J Hematol, 2017, 92(9): 879-884. DOI: 10.1002/ajh.24792.
pmid: 28512788 |
| [4] |
Scott LJ. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma[J]. Drugs, 2017, 77(4): 435-445. DOI: 10.1007/s40265-017-0705-5.
pmid: 28190142 |
| [5] | Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development[J]. Bioconjug Chem, 2015, 26(2): 176-192. DOI: 10.1021/bc5004982. |
| [6] | Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase Ⅱ CheckMate 205 trial[J]. J Clin Oncol, 2018, 36(14): 1428-1439. DOI: 10.1200/JCO.2017.76.0793. |
| [7] | Song YQ, Wu JQ, Chen XC, et al. A single-arm, multicenter, phase Ⅱ study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(24): 7363-7369. DOI: 10.1158/1078-0432.CCR-19-1680. |
| [8] | 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南(2022年版)[J]. 中华血液学杂志, 2022, 43(9): 705-715. DOI: 10.3760/cma.j.issn.0253-2727.2022.09.001. |
| [9] |
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068. DOI: 10.1200/JCO.2013.54.8800.
pmid: 25113753 |
| [10] | Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92. DOI: 10.1016/j.ad.2019.05.009. |
| [11] |
Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin's lymphoma: a review of current regimens and outcomes[J]. J Blood Med, 2020, 11: 389-403. DOI: 10.2147/JBM.S250581.
pmid: 33149713 |
| [12] |
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma[J]. J Clin Oncol, 2012, 30(18): 2183-2189. DOI: 10.1200/JCO.2011.38.0410.
pmid: 22454421 |
| [13] |
Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma[J]. Blood, 2016, 128(12): 1562-1566. DOI: 10.1182/blood-2016-02-699850.
pmid: 27432875 |
| [14] |
Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma[J]. Blood, 2015, 125(8): 1236-1243. DOI: 10.1182/blood-2014-08-595801.
pmid: 25533035 |
| [15] | Walewski J, Hellmann A, Siritanaratkul N, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy[J]. Br J Haematol, 2018, 183(3): 400-410. DOI: 10.1111/bjh.15539. |
| [16] | Plattel WJ, Bergamasco A, Trinchese F, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis[J]. Leuk Lymphoma, 2021, 62(14): 3320-3332. DOI: 10.1080/10428194.2021.1957865. |
| [17] |
LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma[J]. Blood, 2018, 132(1): 40-48. DOI: 10.1182/blood-2017-11-815183.
pmid: 29703778 |
| [18] |
Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi[J]. Blood Cancer J, 2019, 9(12): 100. DOI: 10.1038/s41408-019-0265-x.
pmid: 31827067 |
| [19] |
Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage Ⅲ or Ⅳ classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial[J]. Lancet Haematol, 2021, 8(6): e410-e421. DOI: 10.1016/S2352-3026(21)00102-2.
pmid: 34048680 |
| [20] |
Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)[J]. Ann Oncol, 2019, 30(4): 612-620. DOI: 10.1093/annonc/mdz009.
pmid: 31987279 |
| [21] | Hagenbeek A, Mooij H, Zijlstra J, et al. Phase Ⅰ dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study[J]. Haematologica, 2019, 104(4): e151-e153. DOI: 10.3324/haematol.2018.196899. |
| [22] |
Cole PD, McCarten KM, Pei QL, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial[J]. Lancet Oncol, 2018, 19(9): 1229-1238. DOI: 10.1016/S1470-2045(18)30426-1.
pmid: 30122620 |
| [23] |
Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older[J]. Blood, 2015, 126(26): 2798-2804. DOI: 10.1182/blood-2015-06-644336.
pmid: 26377597 |
| [24] |
Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL[J]. Blood, 2017, 130(26): 2829-2837. DOI: 10.1182/blood-2017-06-787200.
pmid: 29038340 |
| [25] |
Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma[J]. Blood, 2018, 131(11): 1183-1194. DOI: 10.1182/blood-2017-10-811224.
pmid: 29229594 |
| [26] |
Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results[J]. Blood, 2021, 138(6): 427-438. DOI: 10.1182/blood.2020009178.
pmid: 33827139 |
| [27] | Herrera AF, Chen L, Nieto Y, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial[J]. Lancet Haematol, 2023, 10(1): e14-e23. DOI: 10.1016/S2352-3026(22)00318-0. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
